Lavipharm (Greece) Analysis
| LAVI Stock | EUR 1.37 0.04 3.01% |
Lavipharm's financial leverage is the degree to which the firm utilizes its fixed-income securities and uses equity to finance projects. Companies with high leverage are usually considered to be at financial risk. Lavipharm's financial risk is the risk to Lavipharm stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Given that Lavipharm's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Lavipharm is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Lavipharm to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Lavipharm is said to be less leveraged. If creditors hold a majority of Lavipharm's assets, the Company is said to be highly leveraged.
Lavipharm SA is overvalued with Real Value of 1.05 and Hype Value of 1.37. The main objective of Lavipharm stock analysis is to determine its intrinsic value, which is an estimate of what Lavipharm SA is worth, separate from its market price. There are two main types of Lavipharm's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Lavipharm's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Lavipharm's stock to identify patterns and trends that may indicate its future price movements.
The Lavipharm stock is traded in Greece on Athens Exchange, with the market opening at 10:15:00 and closing at 17:20:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Greece. Lavipharm is usually not traded on OhiDay, Christmas Eve, Christmas Day, New Year 's Day, Epiphany, CleanMonday, IndependenceDay, Good Friday, Easter Monday, International Workers ' Day, Whitmonday. Lavipharm Stock trading window is adjusted to Europe/Athens timezone.
Lavipharm |
Lavipharm Stock Analysis Notes
About 67.0% of the company outstanding shares are owned by corporate insiders. The company last dividend was issued on the 20th of August 2007. Lavipharm SA had 1:3 split on the 1st of August 2022. Lavipharm S.A. develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. Lavipharm S.A. was founded in 1911 and is based in Paiania, Greece. LAVIPHARM operates under Drug Manufacturers - Major classification in Greece and is traded on Athens Stock Exchange. To find out more about Lavipharm SA contact the company at 30 210 66 91 000 or learn more at https://www.lavipharm.gr.Lavipharm SA Investment Alerts
| Lavipharm SA may become a speculative penny stock | |
| Lavipharm SA appears to be risky and price may revert if volatility continues | |
| About 67.0% of the company outstanding shares are owned by corporate insiders |
Lavipharm Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.56 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Lavipharm's market, we take the total number of its shares issued and multiply it by Lavipharm's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Lavipharm Profitablity
Lavipharm's profitability indicators refer to fundamental financial ratios that showcase Lavipharm's ability to generate income relative to its revenue or operating costs. If, let's say, Lavipharm is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Lavipharm's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Lavipharm's profitability requires more research than a typical breakdown of Lavipharm's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.02 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.08 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.08. Technical Drivers
As of the 19th of February, Lavipharm secures the Risk Adjusted Performance of 0.2254, mean deviation of 2.03, and Downside Deviation of 2.57. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lavipharm SA, as well as the relationship between them.Lavipharm SA Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two.
Lavipharm Outstanding Bonds
Lavipharm issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Lavipharm SA uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Lavipharm bonds can be classified according to their maturity, which is the date when Lavipharm SA has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Lavipharm Predictive Daily Indicators
Lavipharm intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Lavipharm stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Lavipharm Forecast Models
Lavipharm's time-series forecasting models are one of many Lavipharm's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lavipharm's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Lavipharm SA Debt to Cash Allocation
Lavipharm SA has accumulated 40.54 M in total debt. Lavipharm SA has a current ratio of 1.26, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Lavipharm until it has trouble settling it off, either with new capital or with free cash flow. So, Lavipharm's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Lavipharm SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Lavipharm to invest in growth at high rates of return. When we think about Lavipharm's use of debt, we should always consider it together with cash and equity.Lavipharm Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Lavipharm's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Lavipharm, which in turn will lower the firm's financial flexibility.Lavipharm Corporate Bonds Issued
About Lavipharm Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Lavipharm prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Lavipharm shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Lavipharm. By using and applying Lavipharm Stock analysis, traders can create a robust methodology for identifying Lavipharm entry and exit points for their positions.
Lavipharm S.A. develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. Lavipharm S.A. was founded in 1911 and is based in Paiania, Greece. LAVIPHARM operates under Drug Manufacturers - Major classification in Greece and is traded on Athens Stock Exchange.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Lavipharm to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Watchlist Optimization Now
Watchlist OptimizationOptimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
| All Next | Launch Module |
Additional Tools for Lavipharm Stock Analysis
When running Lavipharm's price analysis, check to measure Lavipharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lavipharm is operating at the current time. Most of Lavipharm's value examination focuses on studying past and present price action to predict the probability of Lavipharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lavipharm's price. Additionally, you may evaluate how the addition of Lavipharm to your portfolios can decrease your overall portfolio volatility.